Analysts Expect Ovid Therapeutics Inc (NASDAQ:OVID) to Post -$0.49 Earnings Per Share

Equities analysts expect Ovid Therapeutics Inc (NASDAQ:OVID) to announce ($0.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.46). Ovid Therapeutics posted earnings per share of ($0.53) in the same quarter last year, which would suggest a positive year over year growth rate of 7.5%. The business is scheduled to announce its next earnings results on Thursday, August 8th.

On average, analysts expect that Ovid Therapeutics will report full-year earnings of ($1.84) per share for the current financial year, with EPS estimates ranging from ($2.15) to ($1.52). For the next year, analysts anticipate that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($4.55) to ($0.53). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Ovid Therapeutics.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

A number of research analysts recently commented on OVID shares. Zacks Investment Research lowered Ovid Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Cowen restated a “buy” rating on shares of Ovid Therapeutics in a research note on Sunday, May 12th. ValuEngine lowered Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. LADENBURG THALM/SH SH restated a “buy” rating and issued a $27.00 target price on shares of Ovid Therapeutics in a research note on Thursday, May 16th. Finally, Piper Jaffray Companies cut their target price on Ovid Therapeutics to $14.00 and set an “overweight” rating for the company in a research note on Sunday, March 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Ovid Therapeutics currently has an average rating of “Buy” and a consensus price target of $12.85.

Several hedge funds and other institutional investors have recently modified their holdings of OVID. Acadian Asset Management LLC raised its stake in Ovid Therapeutics by 445.6% during the first quarter. Acadian Asset Management LLC now owns 153,898 shares of the company’s stock worth $272,000 after acquiring an additional 125,690 shares in the last quarter. Two Sigma Investments LP acquired a new position in Ovid Therapeutics during the fourth quarter worth $114,000. SG Americas Securities LLC acquired a new position in Ovid Therapeutics during the fourth quarter worth $46,000. Dimensional Fund Advisors LP raised its stake in Ovid Therapeutics by 11.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock worth $211,000 after acquiring an additional 8,995 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Ovid Therapeutics by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock worth $231,000 after acquiring an additional 6,391 shares in the last quarter. Institutional investors and hedge funds own 31.73% of the company’s stock.

Shares of OVID traded down $0.01 during mid-day trading on Monday, hitting $1.77. The company’s stock had a trading volume of 1,719 shares, compared to its average volume of 151,817. Ovid Therapeutics has a one year low of $1.53 and a one year high of $11.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.78. The firm has a market capitalization of $68.49 million, a price-to-earnings ratio of -0.84 and a beta of 2.12. The business has a 50-day moving average of $1.73.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Read More: What does an equal weight rating mean?

Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.